Product Images Rivastigmine Tartrate

This is a medicine called Rivastigmine Tartrate Capsules manufactured by Macleods Pharma USA. Each capsule contains 1.5 mg of Rivastigmine Tartrate. The usual dosage and administration details can be found in the prescribing information. It should be stored at a temperature between 20 to 25°C and should be kept in a tight container. The expiration date is also provided.*

The text refers to a medication named Macleodd, which comes in capsule form. Each capsule contains an unidentified substance. The label identifies the batch number and states that the product should be stored at room temperature in a tight container. The drug also has a usual dosage, which is not specified on the label. It was manufactured in India and it was distributed by Macleods Pharma USA. The text recommends checking the prescribing information for dosage and administration instructions.*

MACLEODS 'Each' capsule contains Rivastigime Tartrato equivalent to Rivastigmine of 4.5 mg. It is a Pharma USA product and is usually prescribed as per the instructions provided in the Prescribing Information. It is manufactured and distributed by Macleods Pharma USA and Macleods Pharmaceuticals Ltd. respectively. The capsules should be stored in a tight container at 20° to 25°C (68° to 77°F) with permissible excursions ranging from 15° to 30°C (59° to 86°F). The product is available in batches with Code number DD/DRUGS/DD/375 PM01730701, and contains only 60 capsules.*

This is a prescription medicine called Rivastigmine Tartrate sold in capsule form by Macleods Pharma USA. Each capsule contains 6 mg of Rivastigmine Tartrate, an active ingredient used to treat dementia associated with Alzheimer's or Parkinson's disease. It is available in a batch of 60 capsules and should be stored in a tight container at room temperature. The NDC number for this medicine is 33342-092-09, and its equivalent Pharma USA product is Rivastigmine 6 mg. For further details on the dosage and administration, please refer to the prescribing information. This medicine is manufactured by Macleods Pharmaceuticals Ltd in Daman, India.*

This is a description of a prescription medication called Rivastigmine Tartrate Capsules, USP. The medication comes in a pack of 100 capsules (10 x 10 unit-dose capsules) and is manufactured by Macleods Pharmaceuticals Limited in Daman (India). Each capsule contains 1.5mg of rivastigmine tartrate. The typical dosage should be taken as prescribed in the prescribing information. The medication should be stored at a temperature between 20°C-25°C, with permitted excursions between 15°C-30°C. The blister pack is not child resistant.*

Rivastigmine Tartrate Capsules, USP are a form of medication that comes in a package of 30 capsules, with each capsule containing 1.5 mg of the active ingredient. The National Drug Code for this medication is 33342-089-06. There seems to be some errors in the text but the description provides information about the medication's strength, the packaging, and the drug code.*

Rivastigmine Tartrate Capsules, USP is a medication used for the treatment of mild to moderate dementia associated with Alzheimer's or Parkinson's disease. It is manufactured by Macleods Pharma USA and comes in a bottle containing 100 capsules. Each capsule contains Rivastigmine Tartrate, equivalent to 3mg, and should be stored in a cool dry place between 20°C to 25°C (68°F to 77°F). The usual dosage can be found in the prescribing information, however, it is recommended to consult a doctor before taking this medication. The blister pack is not child resistant.*

NDC No.33342-090-06 is a label for Rivastigmine Tartrate Capsules, USP that comes in a package of 30 capsules. The rest of the text is not readable.*

This is a description of Rivastigmine Tartrate Capsules by Nocieods Pharma USA Inc. They contain Rivastigmine Tartrate and are packaged in a blister pack with 100 capsules in it. The recommended storage temperature is 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F). The usual dosage information is available in the prescribing information. The text also mentions that the blister pack is not child-resistant.*

This is a description for Rivastigmine Tartrate Capsules, a medication with the NDC No. 33342-091-06. The text includes the name of the drug, the manufacturer, the number of capsules per bottle, and some numbers that might be related to dosage or inventory. The rest of the text appears to be random characters and is not readable.*

This is a description for a medication called Rivastigmine Tartrate Capsules, USP with a National Drug Code of 33342-092-12. The medication is intended to be administered through a prescription from a healthcare provider. Each bottle contains 100 capsules and should be stored in a cool, dry place. The drug is manufactured by Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Limited. The recommended dosage should be obtained from the prescribing information which may vary from patient to patient.*

This is a description of a drug with the NDC code 33342-092-06, which is Rivastigmine Tartrate Capsules. The drug comes in a size of 30 capsules and has the brand name Macleody. There seems to be a table of some sort containing different values such as 0.08, 0.52 and 0.89. There are also various abbreviations such as supuBRseAly and popsusod suorsname with no context available. The text is not very useful in providing a comprehensive description of the product.*

The text provided seems to be a table or a chart, showing different treatment groups with their respective results. It includes some numerical values and symbols, such as "+" and "-". It appears to be related to medical research, specifically evaluating the change in ADAS-cog (probably a cognitive assessment tool) in different groups of patients. However, without a proper context or clear headings, it is difficult to provide a more accurate description.*

This seems to be a table displaying the percentage of patients who experienced improvement or worsening depending on the dosage of a drug (possibly placebo) they were given, as well as their CIBIC-Plus rating. The dosage levels mentioned are 0-4mg and 6-12mg. However, without additional context or information, it is difficult to determine the exact drug being referred to or the condition it is being used to treat.*

This appears to be a table showing the mean change from baseline in ADAS-cog (a measurement of cognitive function) rating during a 18 week treatment. The table also includes two columns labeled "Clinical Improvement" and "Clinical Decline". The percentage value of "2%" likely refers to the magnitude of change observed during treatment.*

This is a graph comparing cumulative percentage of patients with change in ADAS-cog score. The x-axis shows the change from baseline and the y-axis shows the percentage of patients. Different treatment groups are represented by different colored lines. Additionally, there is a table with numerical values showing the percentage of patients at specified ADAS-cog score changes for each treatment group.*

The text describes a clinical study evaluating the mean change from baseline in ADAS-cog Rating after 14 weeks of treatment with either rivastigmine or a placebo. The results indicate a clinical improvement with rivastigmine and decline with the placebo. Standard error of the mean is also mentioned.*

This text appears to be a table or chart depicting the percentage of patients in a study who were taking Rivastigmine compared to a placebo, and how they rated on the ADCS-CGIC scale (which assesses change in cognitive function in patients with Alzheimer's disease). The chart shows different levels of improvement or worsening in cognitive function, ranging from "markedly improved" to "markedly worse," for both Rivastigmine and placebo groups.*